PLERIXAFOR
|
- ₹4800 - ₹13800
- Product name: PLERIXAFOR
- CAS: 110078-46-1
- MF: C28H54N8
- MW: 502.78
- EINECS:1592732-453-0
- MDL Number:MFCD05662218
- Synonyms:1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane;1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-;Mozobil;Sdz sid 791;Unii-S915p5499n;1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;Plerixafor(AMD3100);1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylMethyl)phenyl]Methyl}-1,4,8,11-tetraazacyclotetradecane
2 prices
Selected condition：
Brand
- TCI Chemicals (India)
Package
- 50MG
- 250MG
- ManufacturerTCI Chemicals (India)
- Product numberP2678
- Product descriptionPlerixafor min. 98.0 %
- Packaging50MG
- Price₹4800
- Updated2022-05-26
- Buy
- ManufacturerTCI Chemicals (India)
- Product numberP2678
- Product descriptionPlerixafor min. 98.0 %
- Packaging250MG
- Price₹13800
- Updated2022-05-26
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| TCI Chemicals (India) | P2678 | Plerixafor min. 98.0 % | 50MG | ₹4800 | 2022-05-26 | Buy |
| TCI Chemicals (India) | P2678 | Plerixafor min. 98.0 % | 250MG | ₹13800 | 2022-05-26 | Buy |
Properties
Melting point :122-125°C
Boiling point :657.5±55.0 °C(Predicted)
Density :0.962
storage temp. :Keep in dark place,Inert atmosphere,2-8°C
solubility :Methanol (Slightly), Water (Slightly)
form :Solid
pka :10.60±0.20(Predicted)
color :White to Pale Beige
Stability :Hygroscopic
CAS DataBase Reference :110078-46-1
Boiling point :657.5±55.0 °C(Predicted)
Density :0.962
storage temp. :Keep in dark place,Inert atmosphere,2-8°C
solubility :Methanol (Slightly), Water (Slightly)
form :Solid
pka :10.60±0.20(Predicted)
color :White to Pale Beige
Stability :Hygroscopic
CAS DataBase Reference :110078-46-1
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||
| Precautionary statements: |
|
Description
Autologous hematopoietic stem cell (HSC) transplantation, a standard treatment for hematological malignancies, such as non-Hodgkin’s lymphoma or multiple myeloma, involves collection of HSCs from the patient, chemo- or radiotherapy of the patient to eliminate malignant cells, and retransplantation of the stored HSCs.Plerixafor is a potent antagonist of the CXCR4 chemokine receptor and a first-in-class drug for stem cell mobilization. CXCR4 is specific for stromal-derived-factor-1 (SDF-1), a molecule endowed with potent chemotactic activity forlymphocytes. Because the interaction between SDF-1 and CXCR4 plays an important role in holding HSCs in the bone marrow, drugs that block the activity of CXCR4 receptor are capable of mobilizing HSCs into the bloodstream. In vitro, plerixafor potently blocks SDF-1 binding of CXCR4 and inhibits SDF-1-induced calcium flux (IC50 = 0.01-0.13 mg/mL) and chemotaxis (IC50 = 0.13 mg/mL) in several different cell types. Plerixafor, in combination with G-CSF, is specifically indicated to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.
Related product price
- 155148-31-5
₹9380-14970 - Varenicline tartrate
₹15891.1-59797.3 - GSK-3BETA INHIBITOR XII
₹4000-52599.99